Reference no: EM132922154

You need to assume that the technology is new and has not yet been publicly funded. The evaluation should address the following questions:

1. Is pembrolizumab monotherapy for patients with PD-L1 positive, previously untreated, non-small cell lung cancer as, or more, safe and effective than chemotherapy?
o Develop PICO criteria for conducting a systematic review to assess the effectiveness and harm/safety of this health technology.
o Identify 3 pieces of evidence of good quality that address this question and narratively synthesise the findings that have been presented according to the most important patient-relevant outcomes described in your PICO criteria.

2. Broadly describe what you would do to model the results and determine the cost-effectiveness of pembrolizumab monotherapy relative to chemotherapy in patients that have PD-L1 positive, previously untreated non-small cell lung cancer.

o Use a structured approach or checklist as a guide for how to describe this model
o Identify and evaluate the likely applicability, extrapolation and transformation issues associated with applying the evidence identified to the economic model

3. What are the ethical issues associated with testing for PD-L1 positivity and treating with pembrolizumab monotherapy?
o Use an ethics framework or checklist as a guide for how to do this ethical analysis

4. Prepare a 2-page policy brief including a conclusion for your policy maker as to whether the health technology should be publicly funded. This should be included as the first section of your assignment.

5. The whole assignment should be no longer than 12 pages (5500 typed words single-spaced).

Attachment:- PICO criteria.rar